Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Machine-learning for target discovery
February 2020
SHARING OPTIONS:

NEW YORK—Insilico Medicine has found its latest partner in Pfizer Inc., as the companies announced a research collaboration in mid-January to leverage Insilico’s Pandomics Discovery Platform to identify real-world evidence for potential therapeutic targets implicated in several diseases. Financial details were not disclosed. Insilico specializes in machine learning to generate “new molecular structures with the specified parameters, generation of synthetic biological data, target identification and prediction of clinical trials outcomes,” the company says.
 
“We look forward to working with Insilico as Pfizer continues to explore new technologies that may be able to help us identify targets and biomarkers that could assist in our discovery programs, and potentially lead to breakthrough therapeutics for patients with unmet medical needs,” noted Morten Sogaard, vice president, Target Sciences, Pfizer.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.